

Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50206-013003		
				Serial No. 10/654,796		
				Applicant Nicholas P. Barker et al.		
				Filing Date September 3, 2003		
				Group 1614		
				IDS Filed June 23, 2004		
				Customer No. 21559		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)						
(37 C.F.R. § 1.98(b))						
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
BDH	4,647,454	03/03/87	Cymbalista			
	5,349,001	09/20/94	Greenwald et al.			
	5,359,030	10/25/94	Ekwuribe			
	5,382,657	01/17/95	Karasiewicz et al.			
	5,446,090	08/29/95	Harris			
↓	6,296,844	10/02/01	Takahashi			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
BDH	WO 98/16255 A2	04/23/98	PCT			
	WO 00/66137 A1	11/9/00	PCT			
↓	WO 02/32414 A2	04/25/02	PCT			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
BDH	Bailon et al., "Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon α 2a for the treatment of hepatitis C," <i>Bioconjugate Chem.</i> 12:195-202 (2001).					
	Burgess et al., "Abnormal surface distribution of the human asialoglycoprotein receptor in cirrhosis," <i>Hepatology</i> 15:702-706 (1992).					
	Cutrone et al., "Identification of critical residues in bovine IFNAR-1 responsible for interferon binding," <i>J. Biol. Chem.</i> 276:17140-17148 (2001).					
↓	Dotzauer et al., "Hepatitis A virus-specific immunoglobulin A mediates infection of hepatocytes with hepatitis A virus via the asialoglycoprotein receptor," <i>J. Virology</i> 74:10950-10957 (2000).					
EXAMINER	Bruce D. J. L. [Signature]			DATE CONSIDERED 2/26/06		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50206-013003	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))				Serial No.	10/654,796	
				Applicant	Nicholas P. Barker et al.	
				Filing Date	September 3, 2003	
				Group	1614	
				IDS Filed	June 23, 2004	
				Customer No.	21559	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
BDH	Eisenberg et al., "Asialoglycoprotein receptor in human isolated hepatocytes from normal liver and its apparent increase in liver with histological alterations," <i>J. Hepatol.</i> 13:305-309 (1991).					
	Eto et al., "Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon," <i>Nature Medicine</i> 5:577-581 (1999).					
	Glue et al., "Pegylated interferon- α 2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data," <i>Clinical Pharmacology & Therapeutics</i> 68:556-567 (2000).					
	Grace et al., "Structural and biologic characterization of pegylated recombinant IFN- α 2b," <i>J Interferon Cytokine Res.</i> 21:1103-1115 (2001).					
	Harvey et al., "Gonococcal lipooligosaccharide is a ligand for the asialoglycoprotein receptor on human sperm," <i>Mol. Microbiol.</i> 36:1059-1070 (2000).					
	Harvey et al., "Receptor-mediated endocytosis of <i>Neisseria gonorrhoeae</i> into primary human urethral epithelial cells: The role of the asialoglycoprotein receptor," <i>Mol. Microbiol.</i> 42:659-672 (2001).					
	Hirose et al., "Regulation of asialoglycoprotein receptor expression in proliferative state of hepatocytes," <i>Biochem. Biophys. Res. Communications</i> 287:675-681 (2001).					
	Karpusas et al., "The crystal structure of human interferon β at 2.2-Å resolution," <i>Proc. Natl. Acad. Sci. USA</i> 94:11813-11818 (1997).					
	Kasama et al., "Pharmacokinetics and biologic activities of human native and asialointerferon- β s," <i>J. Interferon Cytokine Res.</i> 15:407-415 (1995).					
	Lee et al., "Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin," <i>J. Biolog. Chem.</i> 258:199-202 (1983).					
	Mizuno et al., "Distribution of asialoglycoprotein receptor in human hepatocellular carcinoma," <i>Liver</i> 13:80-85 (1993).					
	Monkarsh et al., "Positional isomers of monopegylated interferon α -2a: Isolation, characterization, and biological activity," <i>Anal. Biochem.</i> 247:434-440 (1997).					
↓	Nyman et al., "Structural characterisation of N-linked and O-linked oligosaccharides derived from interferon- α 2b and interferon- α 14c produced by Sendai-virus-induced human peripheral blood leukocytes," <i>Eur. J. Biochem.</i> 253:485-493 (1998).					
EXAMINER		Bruce D. Givens		DATE CONSIDERED		2/26/06
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						



<p>SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p> <p>(37 C.F.R. § 1.98(b))</p>	Attorney Docket No.	50206-013003
	Serial No.	10/654,796
Applicant	Nicholas P. Barker et al.	
Filing Date	September 3, 2003	
Group	1614	
IDS Filed	June 23, 2004	
Customer No.	21559	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)		
BDH	Pepinsky et al., "Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon- β -1a with preserved in vitro bioactivity," <i>J. Pharmacol. Exp. Ther.</i> 297:1059-1066 (2001).	
	Qin et al., "Interferon- β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice," <i>Proc. Natl. Acad. Sci. USA</i> 95:14411-14416 (1998).	
	Qin et al., "Human and mouse IFN- β gene therapy exhibits different anti-tumor mechanisms in mouse models," <i>Mol. Therapy</i> 4:356-364 (2001).	
	Schering-Plough Research Institute, "Toxicologist's Review of Pegylated Interferon- α 2b (PEG-IFN, PEG-INTRON)," December 19, 2000.	
	Tada et al., "Systemic IFN- β gene therapy results in long-term survival in mice with established colorectal liver metastases," <i>J. Clin. Invest.</i> 108:83-95 (2001).	
	Takahashi et al., "Acute hepatitis in rats expressing human hepatitis B virus transgenes," <i>Proc. Natl. Acad. Sci. USA</i> 92:1470-1474 (1995).	
	Treiber, "Systemic treatment of hepatocellular carcinoma," <i>Dig. Dis.</i> 19:311-323 (2001).	
	Trere et al., "The asialoglycoprotein receptor in human hepatocellular carcinomas: Its expression on proliferating cells," <i>British J. Cancer</i> 81:404-408 (1999).	
	U.S. Food and Drug Administration, Product Approval Information: Peginterferon alfa-2b. May 28, 2002.	
	Uwatoku et al., "Asialoglycoprotein receptors on rat dendritic cells: possible roles for binding with kupffer cells and ingesting virus particles," <i>Arch. Histol. Cytol.</i> 64:223-232 (2001).	
↓	Wang et al., "Identification of the major positional isomer of pegylated interferon alpha-2b," <i>Biochem.</i> 39:10634-10640 (2000).	
EXAMINER <i>Bruce S. Jones</i>	DATE CONSIDERED <i>2/26/06</i>	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.		